Table 1 Participant characteristics at baseline by cognitive status
Characteristics | All (N = 261) | MCI (n = 122) | Normal cognition (n = 139) | p-value |
|---|---|---|---|---|
Female, n (%) | 187 (71.6) | 90 (73.8) | 97 (69.8) | .494 |
Age years, Mean (SD) | 74.4 (6.3) | 75.3 (6.7) | 73.7 (5.8) | .08 |
Education – college or university degree, n (%) | 67 (25.6) | 21 (17.2) | 46 (33.1) | .003* |
Living alone, n (%) | 137 (52.4) | 75 (61.5) | 62 (44.6) | .01* |
MOCAb, Mean score (SD) | 24.5 (2.4) | 23.3 (1.4) | 27.4 (1.3) | .000* |
General health status (poor or fair), n (%) | 88 (32.8) | 49 (32.8) | 44 (31.7) | .895 |
Comorbidities, Mean (SD) | 7.4 (2.5) | 7.2 (2.4) | 7.6 (2.7) | .335 |
Self-reported indication for benzodiazepine: | ||||
Insomniac, n (%) | 159 (60.9) | 73 (59.8) | 86 (61.9) | .417 |
Anxietyc, n (%) | 126 (48.3) | 70 (57.4) | 56 (40.3) | .006* |
Duration of benzodiazepine use (years), Mean (SD) | 10.7 (8.8) | 10.3 (8.0) | 10.9 (9.4) | .548 |
Previous attempts at cessation, n (%) | 119 (45.6) | 52 (42.6) | 67 (48.2) | .321 |
Successful attempts, n (%) | 41 (15.7) | 14 (11.5) | 27 (19.4) | .123 |
Benzodiazepine typed, n (%): | ||||
Short-acting | 70 (26.8) | 36 (29.5) | 34 (24.5) | .358 |
Intermediate acting | 180 (70.0) | 81 (66.4) | 99 (71.2) | .400 |
Long acting | 11 (4.2) | 5 (4.1) | 6 (4.3) | .888 |
Benzodiazepine Equivalent dosea, Mean (SD) | 1.24 (.85) | 1.27 (.75) | 1.25 (.82) | .571 |
Number of medications at baseline | 9.86 (3.7) | 9.72 (3.8) | 9.98 (3.6) | .574 |
Baseline Self-efficacy in tapering benzodiazepine (/100), Mean (SD) | 38.1 (35.6) | 31.2 (34.8) | 44.1 (35.4) | .004* |